Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 420.00
Bid: 410.00
Ask: 430.00
Change: -8.00 (-1.87%)
Spread: 20.00 (4.878%)
Open: 427.50
High: 427.50
Low: 420.00
Prev. Close: 428.00
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

French study shows superiority of Tristel Wipes

1 Dec 2015 11:05

RNS Number : 5512H
Tristel PLC
01 December 2015
 

 

Tristel plc

("Tristel" or "the Company")

 

French study shows superiority of Tristel Wipes System

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces that a French study conducted at a leading university hospital has demonstrated the superiority of its chlorine dioxide wiping method over France's market leader, a peracetic acid soaking method. The methods are alternative ways to disinfect medical instruments used in the Ear, Nose and Throat ("ENT") department of a hospital.

 

The study was undertaken jointly by the infection prevention and ENT departments at the University Hospital, Lille. It focused on the ability of the two disinfectants (Tristel Wipes and Anios Anioxyde 1000) to kill to the requirements of European Standards: a) four different strains of bacteria, and b) a bacterial spore; and the time taken to do so.

 

The Tristel Wipe killed all four bacterial strains in 30 seconds compared to ten minutes for the French product. The Tristel Wipe killed the far more resistant bacterial spore in two minutes, whereas the French product was unable to so in ten minutes. The ability to kill microbes is the most important feature of an instrument disinfectant, but the time taken to do so is almost as important. The duration of the disinfection process is the rate limiting step for an ENT department - the slower it is the fewer the number of patients that can be seen during a clinic.

 

This latest study complements previous published research from the UK, Germany, Italy, New Zealand and Russia that substantiates the benefits of the Tristel Wipes System. During its latest financial year ending 30 June 2015, the Company sold £7.5 million of Wipes worldwide, of which £4.5 million were generated in the UK and £3 million in overseas markets. Tristel has a sales presence in all of the major European countries, but France is its least developed market, and the Company expects this study and other initiatives to accelerate its market penetration there.

 

Paul Swinney, CEO, comments: "We have developed a Wipes business in Germany worth over £1 million in sales, and significant footholds in Spain, Italy, Benelux, and also Scandinavia. Whilst we have a very capable distribution partner in France, the lack of French originated scientific support for our products has held us back in terms of sales. This study is a very positive step forward for us in the French market."

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

 

Liz Dixon, Finance Director

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

finnCap

Tel: 020 7600 1658

Geoff Nash/ Giles Rolls (Corporate Finance)

 

Stephen Norcross (Corporate Broking)

 

   

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUGGCUPUPAGGG
Date   Source Headline
9th Aug 200612:00 pmRNSDirector/PDMR Shareholding
9th Aug 20067:00 amRNSAcquisition update
16th Jun 20063:39 pmRNSDirector/PDMR Shareholding
6th Jun 20067:01 amRNSAcquisition update
26th May 20068:56 amRNSDirector/PDMR Shareholding
25th May 20068:21 amRNSDirector/PDMR Shareholding
24th May 200611:10 amRNSDirector/PDMR Shareholding
23rd May 20067:03 amRNSAcquisition & Trading Update
13th Feb 20067:01 amRNSInterim Results
6th Feb 200611:10 amRNSNotice of Results
23rd Dec 200512:22 pmRNSGrant of Options
15th Nov 200511:36 amRNSAGM Statement
7th Oct 20057:00 amRNSDirector/PDMR Shareholding
5th Oct 20053:29 pmRNSNotice of AGM
4th Oct 20055:18 pmRNSDividend payment date
3rd Oct 20057:00 amRNSFinal Results
19th Sep 20054:08 pmRNSNotice of Results
4th Jul 20057:00 amRNSGrant of Patent

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.